1. 20PDetecting therapy-guiding aberrations in platelets and plasma at the transcriptome level in non-small-cell lung cancer. (7th November 2019) Authors: Meng, P; Rybczynska, A A; Wei, J; Terpstra, M M; Timens, W; Schuuring, E; Hiltermann, T J N; Groen, H J M; Kok, K; Van der Wekken, A J; Van den Berg, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 7 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Detection of known and novel genomic rearrangements by array based comparative genomic hybridisation: deletion of ZNF533 and duplication of CHARGE syndrome genes. Issue 7 (15th April 2008) Authors: Monfort, S; Roselló, M; Orellana, C; Oltra, S; Blesa, D; Kok, K; Ferrer, I; Cigudosa, J C; Martínez, F Journal: Journal of medical genetics Issue: Volume 45:Issue 7(2008) Page Start: 432 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP28 Medical and Surgical Outcomes in Isolated Internal Penetrating Crohn's Disease: A Multi-Centre Experience. (27th May 2021) Authors: Sebepos-Rogers, G; Fragkos, K; Shakweh, E; Shah, K; Lake, L; Balarajah, S; Chung, Y; McGuire, J; Al-Shakarchi, N; Khetan, T; Bottle, J; Anandarajah, C; Meade, S; David, L; Hicks, L; Kok, K; Joshi, N; Samaan, M; Patel, K; Mehta, S Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S066 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Genotype–phenotype correlation in 21 patients with Wolf–Hirschhorn syndrome using high resolution array comparative genome hybridisation (CGH). Issue 2 (14th September 2007) Authors: Maas, N M C; Van Buggenhout, G; Hannes, F; Thienpont, B; Sanlaville, D; Kok, K; Midro, A; Andrieux, J; Anderlid, B-M; Schoumans, J; Hordijk, R; Devriendt, K; Fryns, J-P; Vermeesch, J R Journal: Journal of medical genetics Issue: Volume 45:Issue 2(2008) Page Start: 71 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP03 Anti-SARS-CoV2 antibody responses are attenuated in patients with Inflammatory Bowel Disease treated with infliximab. (27th May 2021) Authors: Kennedy, N A; Goodhand, J; Bewshea, C; Nice, R; Chee, D; Lin, S; Chanchlani, N; Butterworth, J; Cooney, R; Croft, N; Hart, A; Irving, P; Kok, K; Lamb, C; Limdi, J; MacDonald, J; McGovern, D; Mehta, S; Murray, C; Patel, K Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S002 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OP21 COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab. (21st January 2022) Authors: Alexander, J; Kennedy, N; Ibraheim, H; Anandabaskaran, S; Saifuddin, A; Castro Seoane, R; Liu, Z; Nice, R; Bewshea, C; D'Mello, A; Constable, L; Jones, G R; Balarajah, S; Fiorentino, F; Sebastian, S; Irving, P M; Hicks, L; Williams, H; Kent, A; Linger, R Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i022 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OP24 Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with Inflammatory Bowel Disease after three doses of COVID-19 vaccine: a prospective multicentre cohort study. (30th January 2023) Authors: Liu, Z; Le, K; Zhou, X; Alexander, J; Lin, S; Bewshea, C; Chanchlani, N; Nice, R; McDonald, T; Lamb, C; Sebastian, S; Kok, K; Lees, C; Hart, A; Pollok, R; Boyton, R; Altmann, D; Pollock, K; Goodhand, J; Kennedy, N Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. OP37 Bacterial suppression of intestinal fungi via activation of human gut Vδ2+ T-cells. (21st January 2022) Authors: Mathew, L; Savage, M; Pardieu, C; O'Brien, M; Sze, S K; Eberl, M; Stagg, A; Gasparetto, M; Kok, K; Lindsay, J; McCarthy, N Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i043 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. OWE-17 Nutritional care pathways of patients with malignant bowel obstruction: preliminary findings from 8 UK Centres. (June 2019) Authors: Patel, PS; Fragkos, K; Keane, N; Mountford, C; Wilkinson, D; Johnson, A; Naghibi, M; Chan, D; Roberts, B; Neild, P; Metin Devrim, Y; Allan, P; Fitzpatrick, M; Gomez, M; Williams, S; Kok, K; Sharkey, L; Swift, C; Forbes, A; Mehta, S Journal: Gut Issue: Volume 68(2019)Supplement 2 Page Start: A172 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P318 Ustekinumab: early experience and medium-term outcomes from a UK multi-centre real-world cohort. (25th January 2019) Authors: Gadhok, R; Rao, R; Honap, S; Samaan, M; Harpham-Lockyer, L; Kwok, H; Whitley, L; Ibarra, A; Burgess, N; Seward, E; Parkes, G; Mehta, S; Vega, R; McCartney, S; Bloom, S; Irving, P; Lindsay, J O; Kok, K; Rahman, F Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S260 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗